Lantern Pharma Inc (OQ:LTRN)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Jun 12, 2024 07:30 am ET

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

Lantern Pharma Inc., (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced that the Japan Patent Office (JPO) has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma’s drug candidate LP-284 ((+)N-hydroxy-N-(methylacylfulvene)urea). The Certificate of Patent entitled “Illudin Analogs, Uses Thereof, and Methods for Synthesizin

May 06, 2024 03:00 am ET

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company,

May 02, 2024 07:30 am ET

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Apr 24, 2024 08:00 am ET

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that – the company has launched Webinar Wednesdays, a webinar series that focuses on areas of high oncology drug development interest with leading physicians, scientists and Lantern collaborators in drug development and artificial intelligence. The series begins today, Wednesday, April 24, 2024, and is planned to be he

Apr 22, 2024 08:12 am ET

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Mar 20, 2024 09:00 am ET

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

FN Media Group News Commentary - The use of Artificial Intelligence (AI) in medical diagnosis is taking broad strides in recent years and is projected to continue at a high rate in coming years. A report from MarketsAndMarkets opined that the...

Mar 18, 2024 04:02 pm ET

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Mar 15, 2024 08:00 am ET

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first two patients in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-284 in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double hit lymphoma (DHL) and other high-grade B-cell lymphomas (HGBL) as well as other select sol

Mar 11, 2024 07:30 am ET

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Mar 05, 2024 08:01 am ET

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW. The conference will be on Thursday, March 7th, and is a virtual event.

Mar 04, 2024 08:01 am ET

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Dev

Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced a series of important milestones related to the development, size, and advancement of RADR® -- its proprietary AI platform focused on transforming the cost, pace, and timeline of oncology drug development.

Feb 15, 2024 08:01 am ET

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced an important milestone in its antibody-drug conjugate (ADC) program. In collaboration with Bielefeld University, Lantern has generated a new class of highly specific and highly potent ADCs with a cryptophycin drug-payload.

Jan 17, 2024 07:30 am ET

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D. has joined Starlight as its Chief Medical Officer. Dr. Chamberlain will oversee Starlight’s clinical operations, which currently include planned clinical trials for glioblastoma and other high-grade gliomas, brain metastases in adults, and atypical teratoid rhabdoid tumors (ATRT), and diffuse pontine glioma (DIPG) in children. In h

Nov 30, 2023 08:00 am ET

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of high-grade B-cell lymphoma with MYC and BCL2 rearrangements.

Nov 08, 2023 04:01 pm ET

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

Nov 01, 2023 08:00 am ET

Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET

Oct 10, 2023 08:00 am ET

Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET

Oct 03, 2023 08:00 am ET

Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced that in vivo data highlighting the enhanced efficacy of Lantern’s drug candidate LP-184 in glioblastoma (GBM) were published in Clinical Cancer Research, a journal of the American Association for Cancer Research. LP-184 is a unique small molecule with low nanomolar activity and favorable CNS penetration. LP-184 ut

Sep 25, 2023 08:30 am ET

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced the dosing of the first patient in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-184 in patients with advanced solid tumors.

Sep 18, 2023 09:00 am ET

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-284. LP-284 is being developed for the treatment of relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double hit lymphoma (DHL) and other high-grade B-cell lymph

Aug 31, 2023 08:00 am ET

Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced that it will present positive data highlighting the anti-tumor potency of its drug candidate LP-284 for non-Hodgkin’s lymphoma (NHL) at the Society of Hematologic Oncology (SOHO) Eleventh Annual Meeting occurring on Sept. 6 – 9, 2023, at the George R. Brown Convention Center in Houston, Texas.

Aug 28, 2023 08:00 am ET

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced a substantial increase in the power and capabilities of RADR® focused on improving the drug development process for immune checkpoint inhibitors (ICIs). These capabilities are expected to address the multiple challenges facing the increased usage of ICIs in cancer therapy. Since gaining regulatory approval in 2011, I

Aug 14, 2023 08:30 am ET

Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (ML) platform with multiple clinical-stage drug programs, received a notice of allowance from the United States Patent and Trademark Office (USPTO) covering a method of treatment for Atypical Teratoid Rhabdoid Tumor (ATRT) using LP-184, an aggressive and rapidly growing form of cancer of the central nervous system (CNS).

Aug 09, 2023 04:01 pm ET

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights

Aug 02, 2023 12:45 pm ET

RedChip Launches 'Small Stocks, Big Money' Podcast

New podcast series shines a spotlight on undervalued small-cap and microcap stocks

Aug 02, 2023 08:00 am ET

Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its second quarter 2023 operating and financial results webcast on Wednesday, August 9, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Jul 17, 2023 08:00 am ET

Lantern Pharma to Participate and Present at Multiple Upcoming Conferences

Jun 26, 2023 08:30 am ET

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgk

Jun 12, 2023 08:30 am ET

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumors and central nervous system (CNS) cancers. The first-in-human Phase 1A trial for LP-184 is anticipated to launch and dose its first patient during t

Jun 08, 2023 09:00 am ET

Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University

May 17, 2023 08:00 am ET

Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, CEO and President, will present at the Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023. The fireside chat-style webcast will be available to all registered attendees. Details of the webcast can be found below:

May 09, 2023 04:01 pm ET

Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights

May 03, 2023 09:00 am ET

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

BELTSVILLE, Md., May 3, 2023 /CNW/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)". The Harmonic™ study is being conducted to determine clinical advantages for Lantern Pharma's investigational new drug LP-300 in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with tyrosine kinase inhibitors (TKIs).

May 03, 2023 09:00 am ET

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)". The Harmonic™ study is being conducted to determine clinical advantages for Lantern Pharma's investigational new drug LP-300 in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with tyrosine kinase inhibitors (TKIs).

May 02, 2023 04:01 pm ET

Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its first quarter 2023 operating and financial results webcast on Tuesday, May 9, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

May 02, 2023 07:30 am ET

Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has developed highly-accurate and industry-leading AI algorithms to predict the ability of a drug or compound to pass the blood-brain-barrier (BBB), a highly selective border that can prevent drugs from entering brain tissues. The BBB prevents an estimated 98% of drugs from entering the brain, which pre

Apr 13, 2023 07:30 am ET

Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. patent application no. 17/192,838 directed to Lantern Pharma’s drug candidate LP-284 ((+)N-hydroxy-N-(methylacylfulvene)urea). The allowed application entitled “Illudin Analogs, Uses Thereof, and Methods for Syn

Mar 28, 2023 08:00 am ET

Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the dosing of the first patient in the Phase 2 Harmonic™ clinical trial evaluating Lantern’s investigational new drug LP-300 in combination with chemotherapy for never smokers with advanced non-small cell lung cancer (NSCLC).

Mar 21, 2023 04:01 pm ET

Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

Mar 20, 2023 04:01 pm ET

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights

Mar 15, 2023 08:00 am ET

Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company will present at the American Association for Cancer Research (AACR) Annual Meeting. Details on the AACR presentation are provided below:

Mar 13, 2023 08:00 am ET

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its fourth quarter and fiscal year 2022 financial results webcast on Monday, March 20, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Mar 13, 2023 06:00 am ET

Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that neither Lantern Pharma Inc. nor any of its subsidiaries had any exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank. Lantern’s cash, cash equivalents, and marketable securities are managed across top-tier financial institutions and with a multiple-tiered account approach. Lantern’s cash,

Mar 09, 2023 08:00 am ET

Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced new data for its product candidate LP-100 supporting the development of LP-100 in combination with the class of anticancer agents known as PARP inhibitors (PARPi).

Mar 08, 2023 08:00 am ET

Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on March 21, 2023 at 12:00 p.m. ET focusing on synthetic lethality, the unique and powerful mechanism of action behind Lantern’s drug candidates LP-184, LP-284, and LP-100.

Mar 06, 2023 08:00 am ET

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has formed a wholly-owned subsidiary, Starlight Therapeutics Inc. (“Starlight”), to develop drug candidate LP-184’s central nervous system (CNS) and brain cancer indications – including glioblastoma (GBM), brain metastases (brain mets.), and several rare pediatric CNS cancers. Starlight will refer to the mo

Mar 02, 2023 08:00 am ET

Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo M.D., M.Sc., MBA, as Vice President of Clinical Development, and several additional team members. The expansion of the clinical development team will continue to advance the

Feb 27, 2023 08:00 am ET

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has entered into a research and development collaboration with TTC Oncology. The collaboration will focus on leveraging RADR® AI insights to advance TTC Oncology’s first- and best-in-class drug candidate TTC-352 for recurrent ER+ breast cancer patients and additional patient populations poten

Feb 15, 2023 08:00 am ET

Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("AI") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced expansions and updates to RADR®’s product roadmap, which will further enhance its oncology drug discovery capabilities. These RADR® advancements will focus on additional innovative AI and ML approaches to develop Antibody Drug Conjugates (ADCs), which are highly specific cancer-targeted an

Jan 17, 2023 08:00 am ET

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has received guidance from the United States Food and Drug Administration (FDA) on Lantern’s clinical development plans for its LP-184 program. LP-184 has shown nanomolar potency across a range of cancers including several solid tumors and multiple adult and pediatric central nervous system (CNS) cancers

Jan 05, 2023 08:59 am ET

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of mantle cell lymphoma (MCL). MCL is a rare and aggressive form of B-cell non-Hodgkin's lymphoma (NHL) that is typically diagnosed at advanced stages in elderly patients. As nearly all MCL pa

Dec 15, 2022 08:00 am ET

Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it presented new positive preclinical data for its drug candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology Annual meeting.

Dec 13, 2022 08:00 am ET

Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has expanded development of its drug candidate LP-184 to include Triple Negative Breast Cancer (TNBC), one of the most aggressive and malignant forms of breast cancer. New positive preclinical data on the anti-tumor potency of LP-184 for TNBCs was recently presented at the San Antonio Breast Cancer

Dec 02, 2022 08:00 am ET

Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET

via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of...

Nov 22, 2022 08:00 am ET

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it presented positive preclinical data on the efficacy of its drug candidate LP-184 for glioblastoma (GBM), used alone or in combination with the Food and Drug Administration (FDA) approved agent spironolactone, at the Society for Neuro-Oncology (SNO) annual meeting.

Nov 07, 2022 04:01 pm ET

Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights

Nov 02, 2022 08:00 am ET

Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4

Oct 31, 2022 08:00 am ET

Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its third quarter 2022 financial results webcast on Monday, November 7, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Oct 25, 2022 08:00 am ET

Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences

Oct 21, 2022 07:00 am ET

Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference, which is being held on October 26th, 2022 in New York, NY.

Oct 20, 2022 07:59 am ET

Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,471,431, for Lantern’s drug candidate LP-300, which is in a Phase 2 clinical trial,

Oct 11, 2022 04:00 pm ET

Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET

DALLAS, TX / ACCESSWIRE / October 11, 2022 / Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, has been invited to present at the Microcap Rodeo presents The Windy City Roundup 2022 conference, which is being held live, in-person on October 12th - 13th, 2022. CEO & President, Panna Sharma

Oct 05, 2022 08:00 am ET

Lantern Pharma to Present at Upcoming Investor Conferences

Sep 27, 2022 09:05 am ET

60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago

RALEIGH, NC / ACCESSWIRE / September 27, 2022 / The 2nd Annual MicroCap Rodeo Conference is going on the road and will take place at the Swissotel in Chicago on October 12th - 13th, 2022, where 60+ SmallCap, MicroCap and NanoCap public companies will be presenting to a global investor audience.

Sep 23, 2022 08:50 am ET

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will present preclinical data on the potency of Lantern’s drug candidate LP-284 for mantle cell lymphoma (MCL) and several other non-Hodgkin’s lymphomas at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting, Sept. 28 – Oct. 1, 2022, in Houston, TX.

Sep 19, 2022 08:50 am ET

Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on Sept. 22, 2022 at 12:00 p.m. ET. The webinar will focus on challenges in drug development for pediatric cancers and the potential of Lantern’s drug candidates LP-184 and LP-284 for several rare pediatric cancers.

Sep 14, 2022 08:50 am ET

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer

Aug 30, 2022 09:00 am ET

Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright’s 24th Annual Global Investment Conference in September 2022

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company’s CEO & President, Panna Sharma, will be speaking at H.C. Wainwright’s 24th Annual Global Investment Conference, which is being held September 12-14, 2022 in New York, NY.

Aug 19, 2022 08:30 am ET

Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

DALLAS, TX / ACCESSWIRE / August 19, 2022 / RedChip Companies will air a new interview on Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("ML") platform to transform the cost, pace, and timeline of oncology drug discovery and development, on The RedChip Money Report® on Bloomberg TV, this Saturday, August 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Aug 08, 2022 04:01 pm ET

Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights

Aug 01, 2022 07:00 am ET

Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host its second quarter 2022 financial results webcast on Monday, August 8th, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Jul 14, 2022 07:00 am ET

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Food and Drug Administration (FDA) has cleared the Company to proceed with its Phase 2 clinical trial, Harmonic™, for its investigational new drug LP-300. The Harmonic™ trial will be a 90 patient, multi-center, two arm, open-label, and ran

May 12, 2022 07:00 am ET

Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month

DALLAS, May 12, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on May 26th, 2022 at 12:00 p.m. ET. The webinar will focus on glioblastoma multiforme (GBM) and the potential of Lantern's drug candidate LP-184 for GBM as well as other brain cancers.

May 05, 2022 07:00 am ET

Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company’s management will be speaking at five investor and scientific conferences in May 2022.

May 03, 2022 04:01 pm ET

Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights

RADR®, Lantern's proprietary A.I. and machine learning platform, has now surpassed 20 billion data points, enhancing its precision, insights, and capabilities for oncology drug discoveryLaunch and enrollment of the HARMONIC™ clinical trial expected in Summer of 2022; the Phase 2 trial is for LP-300 in never-smokers with lung cancerIND application for LP-184 targeted for submission with the FDA in Q3 2022; enabling a first in-human clinical trial for genomically defined solid tumorsAnnounced brain metastases as a new indication being pursued for LP-184 at the American Association of Cancer Re

Apr 26, 2022 07:15 am ET

Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors

DALLAS, April 26, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Maria L. Maccecchini, Ph.D. has been named as a nominee for election to Lantern's Board of Directors. Dr. Maccecchini will be presented alongside a slate of five existing Directors at Lantern's upcoming Annual Meeting to be held on June 8, 2022.

Apr 22, 2022 07:00 am ET

Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET

DALLAS, April 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, after the financial markets close. The company will host a conference call and webcast in a webinar format at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Tuesday, May 3, 2022.

Apr 14, 2022 11:10 am ET

Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / April 14, 2022 / RedChip Companies, Inc. today announced that Lantern Pharma (NASDAQ:LTRN),a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, will appear on The RedChip Money Report® on Bloomberg TV, April 16, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.

Mar 22, 2022 07:00 am ET

Lantern Pharma Announces Extension of Existing Share Repurchase Program

DALLAS, March 22, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its Board of Directors has authorized an extension through July 31, 2022 of Lantern's existing share repurchase program to acquire up to $7 million of the Company's common stock.

Mar 14, 2022 07:00 am ET

Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting

LP-184 demonstrated anti-tumor activity in brain metastases cell models from lung, skin, and breast cancers. Brain metastases in the U.S. can occur in 10-30% of all cancer cases and are diagnosed in over 100,000 patients each year. Data supports continued development of LP-184 in CNS cancer indications where there is an urgent and unmet clinical need. DALLAS, March 14, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace,

Mar 10, 2022 03:05 pm ET

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights

DALLAS, March 10, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results and operational highlights for the fourth quarter and fiscal year ended December 31, 2021.

Mar 03, 2022 06:00 am ET

Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

DALLAS, March 3, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today that it will host a conference call on Thursday, March 10th, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Feb 15, 2022 05:59 am ET

Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio

DALLAS, Feb. 15, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical stage biopharmaceutical company using its proprietary artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it is expanding opportunities for its portfolio of drug candidates and A.I. drug discovery platform into additional rare pediatric cancers through a collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at the University of Texas Health Science Center at San Antonio (UTHSCSA). GC

Jan 26, 2022 04:30 pm ET

RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28

ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce its partnership with Benzinga to host an exclusive series of CEO interviews on January 28, beginning at 9:15 a.m. ET.

Jan 18, 2022 05:30 am ET

Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors

DALLAS, Jan. 18, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a collaboration and research agreement with The Danish Cancer Society Research Center (DCRC) to support clinical development of Lantern's acylfulvene class drug candidates, LP-100 and LP-184, as well as the development of improved diagnostic methods to identify nucleotide excision repair (NER) deficient tumors. L

Jan 12, 2022 05:03 am ET

Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284

DALLAS, Jan. 12, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has expanded its collaboration agreement with the Developmental Therapeutics Branch (DTB) of the National Cancer Institute (NCI) of the National Institutes of Health. The expansion of this collaboration comes after identifying several gene signatures that predict a potential response of a patient's tumor to La

Jan 04, 2022 08:29 am ET

Lantern Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference

DALLAS, Jan. 4, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, Chief Executive Officer and President of Lantern Pharma, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022. The presentation will be conducted as a fireside chat hosted by H.C. Wainwright Senior Biotechnology Analyst and Managing Direct

Dec 14, 2021 08:01 am ET

Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting

DALLAS, Dec. 14, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma presented positive data on the effectiveness of LP-284 in hematologic cancers at the 63rd American Society of Hematology (ASH) Annual Meeting, which was held in-person and virtually from December 11 – 14, 2021. This poster presentation can be viewed on Lantern Pharma's website at: https://www.

Nov 22, 2021 08:00 am ET

Lantern Pharma Announces Share Repurchase Program

DALLAS, Nov. 22, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern" or the "Company"), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its board of directors has authorized a share repurchase program to acquire up to $7 million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the

Nov 12, 2021 08:40 am ET

Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day

DALLAS, Nov. 12, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it will host a virtual Key Opinion Leader (KOL) event regarding the potential treatment of pancreatic cancer utilizing Lantern Pharma's drug candidate LP-184, on World Pancreatic Cancer Day, Thursday, November 18th at 12:00 pm EST.

Nov 11, 2021 08:15 am ET

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting

DALLAS, Nov. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract on the effectiveness of LP-184 in glioblastoma multiforme (GBM) regardless of MGMT status has been accepted as a virtual poster at the upcoming 26th Society for Neuro-Oncology (SNO) Annual Meeting, which is being held in person and virtually from November 18-21, 2021. The abstract i

Nov 09, 2021 08:00 am ET

Lantern Pharma to Participate in Two Upcoming Investor Conferences

DALLAS, Nov. 9, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that management will be participating in two upcoming investor conferences.

Nov 04, 2021 09:37 am ET

Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

DALLAS, Nov. 4, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract on the effectiveness of LP-284 in hematologic cancers has been accepted as a poster at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, which is being held in-person and virtually from December 11 – 14, 2021. The abstract is available online on the ASH website.

Nov 01, 2021 04:05 pm ET

Lantern Pharma Reports Third Quarter 2021 Financial Results and Operating Highlights

Nov 01, 2021 09:15 am ET

Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 10 Billion Datapoints - Significantly Enhancing Precision Medicine Capabilities & Expanding Potenti

DALLAS, Nov. 1, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its proprietary A.I. platform RADR® has exceeded 10.4 billion datapoints. RADR® is Lantern's proprietary integrated A.I. platform for large-scale biomarker and drug-tumor interaction data analytics that leverages machine-learning. RADR® is used to provide mechanistic insights about drug-tumor interactions, pr

Oct 27, 2021 09:05 am ET

Code Ocean Selected by Lantern Pharma to Power A.I. and Computational Biology Research & Data-Driven Oncology Drug Development Collaborations

DALLAS and NEW YORK, Oct. 27, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a collaboration that will power A.I.-driven computational research for oncology-focused drug discovery and development with Code Ocean, the leading computational research environment for sharing scientific discoveries. By leveraging Code Ocean's Compute Capsule® technology, the strategic approach is

Oct 27, 2021 08:02 am ET

Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology Drug Development

NEW YORK and DALLAS, Oct. 27, 2021 /PRNewswire/ -- Code Ocean, the leading computational research environment for sharing scientific discoveries, today announced a collaboration that will power AI-driven computational research for oncology-focused drug discovery with Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development. By leveraging Code Ocean's Compute Capsule® technology, the move will further power Lantern Pharma's

Oct 25, 2021 04:57 pm ET

Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results Conference Call on Monday, November 1, 2021 at 4:30 p.m. ET

DALLAS, Oct. 25, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today that it will host a conference call on Monday, November 1, 2021 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

Oct 04, 2021 04:30 pm ET

36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021

RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th - 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.

Sep 30, 2021 09:00 am ET

Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021

DALLAS, TX / ACCESSWIRE / September 30, 2021 / Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company has been invited to present at the Fall Harvest - Best Ideas from the Buy-Side conference, which is being held virtually on October 5 - 8, 2021. Panna Sharma, Chief Executive Officer and President of Lantern Pharma, will present at the conference.

Sep 28, 2021 09:20 am ET

Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer

DALLAS and COLUMBUS, Ohio, Sept. 28, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development and Deep Lens, a digital healthcare company focused on enabling faster recruitment of the best-suited cancer patients for clinical trials at the time of diagnosis, today announced that they have entered into a strategic collaboration that will leverage Deep Lens' artificial intelligence clinical trial matching

Sep 22, 2021 09:00 am ET

Lantern Pharma CEO to Present at the Benzinga Healthcare Small Cap Conference on September 29th

DALLAS, Sept. 22, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Panna Sharma, President & CEO of Lantern Pharma will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 – 30, 2021.

Sep 07, 2021 09:00 am ET

Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September

DALLAS, Sept. 7, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it will be participating in two upcoming virtual investor conferences.

Sep 02, 2021 08:59 am ET

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate

Aug 30, 2021 08:59 am ET

FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas

DALLAS, Aug. 30, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-184 Orphan Drug Designation (ODD) for the treatment of glioblastoma multiforme (GBM) and other malignant gliomas. This news follows the recent announcement of the FDA granting LP-184 ODD for the treatment of pancreatic cancer.

Aug 19, 2021 08:50 am ET

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration

DALLAS and BALTIMORE, Aug. 19, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company, announced today that a successful preclinical study has shown its drug candidate LP-184 is able to inhibit tumor growth and improve survival in animal models of glioblastoma (GBM). This study was conducted in collaboration with the research group of John Laterra, M.D., Ph.D., at Kennedy Krieger Institute, which is affiliated with Johns Hopkins University. Lantern had previously announced the initiation of this GBM focused collaboration with Dr. Laterra in December of

Aug 16, 2021 08:20 am ET

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer

DALLAS, Aug. 16, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract titled 'LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects' has been accepted as a virtual poster at the upcoming AACR Virtual Special Conference on Pancreatic Cancer being held on September 29-30, 2021.

Aug 11, 2021 08:21 am ET

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer

DALLAS, Aug. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-184 Orphan Drug Designation for the treatment of pancreatic cancer. LP-184 is a small molecule drug candidate and next generation alkylating agent that preferentially damages DNA in cancer cells that over-express certain biomarkers or that harbor mut

Jul 29, 2021 04:01 pm ET

Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights

DALLAS, July 29, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN) ("Lantern"), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced financial results for the second quarter ended June 30, 2021.

Jul 27, 2021 08:00 am ET

Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S

DALLAS, July 27, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has entered into an Asset Purchase Agreement to reacquire global development and commercialization rights for Irofulven (LP-100) from Allarity, formerly known as Oncology Venture. This transaction includes global rights to the clinical stage drug candidate Irofulven (LP-100), as well as the developed clinical

Jul 22, 2021 04:08 pm ET

Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET

DALLAS, July 22, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, July 29, 2021 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss financial and operating results for the second quarter ended June 30, 2021. The call will be led by Panna Sharma, Presiden

Jul 20, 2021 07:00 am ET

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184

DALLAS, July 20, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today positive new data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center. Preclinical data demonstrated that the drug candidate, LP-184, demonstrated significant and rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks. In comp

Jan 20, 2021 03:00 pm ET

Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment Option

DALLAS, Jan. 20, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the closing of its previously announced public offering of 4,928,571 shares of its common stock at a public offering price of $14.00 per share, which includes 642,856 shares sold upon full exercise of the underwriter's option to purchase additional common shares. The gross proceeds from the

Jan 14, 2021 08:30 pm ET

Lantern Pharma Announces Pricing of $60 Million Public Offering

DALLAS, Jan. 14, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 per share, for gross proceeds of $60 million, before deducting underwriting discounts and offering expenses. In addition, Lantern Pharma has granted the underwriters a 45-day option

Jan 04, 2021 06:00 am ET

Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma

DALLAS and LA JOLLA, Calif., Jan. 4, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced that it will be launching the development of its ADC (Antibody Drug Conjugate) program through an evaluation and potential development agreement with Califia Pharma along with other key internal development and computational initiatives. Lantern will potentially leverage

Dec 17, 2020 06:00 am ET

Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma

DALLAS, Dec. 17, 2020 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Kennedy Krieger Institute. The collaboration will focus on the further development of Lantern's LP-184 in glioblastoma multiforme (GBM). Based in Baltimore, Johns Hopkins is a leading

Dec 15, 2020 06:00 am ET

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers

DALLAS, Dec. 15, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. LP-184 is being targeted for treating Glioblastoma Multiforme (GBM), an aggressive malignant form of brain cancer that comprises about 52% of all primary

Nov 24, 2020 06:30 am ET

Lantern Pharma Announces Upcoming Conference Presentations

DALLAS, Nov. 24, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the pace, risk and cost of oncology drug discovery and development, and identify patients who will benefit from its targeted oncology drug candidates, announced that Panna Sharma, CEO and President, will participate in the following investor events in December:

Oct 29, 2020 03:59 pm ET

Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress

DALLAS, Oct. 29, 2020 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary artificial intelligence ("A.I.") platform, RADR® , to transform oncology drug discovery and development, today announced financial results for the third quarter ended September 30, 2020.

Oct 22, 2020 07:00 am ET

Lantern Pharma to Host Third Quarter 2020 Operating and Financial Results Conference Call on October 29, 2020 at 4:00 p.m. ET

DALLAS, Oct. 22, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, October 29, 2020 at 4:00 p.m. ET to discuss financial and operating results for the third quarter ended September 30, 2020.

Aug 05, 2020 09:00 am ET

LD Micro - Announces Preliminary List of Presenters for the LD 500

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Jul 30, 2020 06:57 am ET

Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress

DALLAS, July 30, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, today announced its financial results for the second quarter ended June 30, 2020, and provided an update on its R&D pipeline and other corporate developments.

Jul 24, 2020 07:56 am ET

Lantern Pharma to Host Second Quarter 2020 Operating and Financial Results Conference Call on July 30, 2020

DALLAS, July 24, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development and, identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that it will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m. Eastern Time to discuss financial and operating results for the second quarter ended June 30, 2020.

Jul 20, 2020 07:55 am ET

Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Gliobla

DALLAS, July 20, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence ("A.I."), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced entering into agreements with leading contract manufacturing companies for process development and manufacturing for two of Lantern's oncology drug candidates, LP-300 and LP-184. Lantern Pharma filed an 8-K on Thursday, July 16 describing a recent agreement for

Jul 16, 2020 11:00 am ET

'Zooming with LD' to Feature 10 Distinct Companies July 20th-31st

LOS ANGELES, CA / ACCESSWIRE / July 16, 2020 / LD Micro today announced that it will be hosting ten companies over the final two weeks of July, with a group presentation in the morning, followed by private investor meetings throughout the day.

Jun 29, 2020 08:45 am ET

Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Data Po

Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will...

Jun 17, 2020 09:23 am ET

Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting

Jun 15, 2020 03:53 pm ET

Lantern Pharma Announces Closing of Initial Public Offering

Lantern Pharma Inc. (LTRN) (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients...

Ad blocking detected

Lantern Pharma Inc (OQ:LTRN)

Business Focus: Biotechnology & Medical Research